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Abstract This study aims to assess in residual periodontal
pockets the clinical, microbiological, and local biological
effects of antimicrobial photodynamic therapy (PDT), de-
livered after ultrasonic instrumentation either once or twice
in a 1-week interval. A single center, three-arm randomized
longitudinal study was carried out for 6 months. Twenty-
eight systemically healthy patients on periodontal mainte-
nance with residual pockets (pocket depth (PD) ≥5 mm,
clinical attachment loss ≥2 mm, and bleeding upon probing
(BOP+)) were included. Residual pockets on three teeth,
separated from each other by at least two other teeth, served
as study sites. After ultrasonic debridement, they were ran-
domly assigned to either PDT delivered twice within 1 week
(group A), PDT delivered only once (group B), or sham
treatment without activating the laser (group C). Methylene
blue was applied with a blunt irrigator tip into the pockets.
Sites were irradiated with laser light at a wavelength of
670 nm using a light-diffusing tip introduced into the pocket.
Initial PD was 5.9±0.9, 6.3±1.3, and 6.3±1.5 mm in
groups A, B, and C, respectively, differences being nonsig-
nificant. PD was significantly reduced in all groups. At
month 3, PD was significantly lower in groups A (2.9±
1.1 mm; p=0.04) and B (2.8±1.1 mm; p=0.03) compared
to group C (3.5±1.2 mm). At month 6, none of the sites in
group A had persisting pockets PD >4 mm and BOP+,
whereas two sites in group B and four sites in group C
stayed in this category. Detection frequencies of the studied
microorganisms at >1,000 and >100.000 cells/ml did not
change significantly from baseline to months 3 or 6 in any
group. A significant overall decrease was observed from
baseline to month 6 for C-reactive protein, serum amyloid
A, fibrinogen, procalcitonin, and α-2 macroglobulin. When
looking at the groups separately, C-reactive protein was
significantly lower only if the laser had been activated twice
(p<0.05). Other differences between groups were not signif-
icant. A single or double episodes of PDT had some additional
benefit over ultrasonic instrumentation alone.
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Introduction
Mechanical removal of bacterial biofilm and calculus from
root surfaces is a well-established procedure in the treatment
of periodontal disease. However, mechanical protocols
alone are unable to eliminate all incriminated bacteria
completely, and the persistence of a limited number of
residual pockets with bleeding on probing (BOP+) after
therapy is therefore a reality. Repeated instrumentation in
residual pockets with metal instruments removes a substan-
tial amount of tooth substance over time [1–4], may cause
gingival recession [5, 6], and may induce hypersensitivity of
teeth to thermal and physical stimuli [7]. Various local and
systemic antimicrobial regimens have been proposed for
better suppression of periodontopathic microorganisms.
The repeated use of antibiotics in residual pockets during
maintenance care is, however, not advisable.
Photodynamic therapy (PDT), because of its bactericidal
and detoxification effect, may be a beneficial adjunct to
mechanical periodontal therapy [8]. PDT is based on the
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principle that a photoactive substance, the photosensitizer,
binds to the target cell and can be activated by a light of
suitable wavelength [9]. During the process, free oxygen
radicals are produced which react with the bacteria and their
products and are toxic for them. Gram-positive bacteria are
the most susceptible to PDT, but, by selecting the appropri-
ate photosensitizer and wavelength, Gram-negative bacteria
can be annihilated as well [10].
Efforts were made in three systematic reviews to evaluate
the benefit of PDT for the treatment of periodontitis, either as a
primary mode of treatment or as an adjunct to mechanical
debridement [11–13]. Results were nondefinitive and in part
contradictory with regards to the clinical and microbiological
effects. Clearly, more primary research is necessary to assess
the value of PDT and to determine the factors influencing the
outcomes. While in most studies carried out so far the proce-
dure was applied just once, in some, PDT was provided
multiple times, e.g., five times in a 2-week period [14] or three
times in a 1-week period [15]. It is unclear if repeated PDT
yields better results than a single application.
One approach for evaluating these effects is by monitoring
the biomarkers in the gingival crevicular fluid (GCF) [16, 17].
Among many inflammatory and immune mediators identified
in the GCF, cytokines have attracted particular attention and
are suspected to be involved in both inflammation-related
alteration and repair of the periodontal tissues. Several acute-
phase reactants may be affected by successful periodontal
therapy as well, even though they are produced in tissues
remote from the infection.
In the current study, we tested the benefit of PDT deliv-
ered as adjunct to ultrasonic debridement once or twice in a
1-week interval in patients previously treated for periodon-
titis with residual periodontal pockets.
Materials and methods
This was a single center, examiner-masked, randomized
clinical trial of 6 months in duration with a three-arm,
within-subject parallel design. The Ethical Committee of
the University Hospitals of Geneva approved the protocol.
Research was conducted according to the principles outlined
in the Declaration of Helsinki on human medical experi-
mentation. All participants were informed about the pro-
cedures and signed a consent form in advance of their
inclusion in the study.
Patients
Between September 2009 and June 2011, 28 patients were
recruited in a private dental practice in Geneva. They had
previously been treated for active periodontal disease in the
same practice. Eligible participants were all adults aged 18
or over, in maintenance after completion of comprehensive
periodontal therapy since 3 to 12 months, and with at least
one site in each of three dentition quadrants with a probing
pocket depth (PD) >4 mm, clinical attachment loss (CAL)
>1 mm, and BOP+. The root surfaces at these sites had to be
smooth and free of detectable calculus, and the teeth had to
be without retention factors for plaque (overhanging mar-
gins of restorations or ill-fitting crowns). Appropriate sites
had to be located in the region between the incisors and the
mesial aspect of the first molar and separated from each
other by at least two teeth.
The exclusion criteria were systemic illnesses (i.e., diabetes
mellitus, cancer, HIV, bone metabolic diseases or disorders
that compromise wound healing), radiation or immunosup-
pressive therapy, pregnancy or lactating, systemic antibiotics
taken within the previous 2 months, the use of nonsteroid anti-
inflammatory drugs, and confirmed or suspected allergy/
hypersensitivity to methylene blue. Subjects with physical
limitations or restrictions that might preclude normal oral
hygiene procedures were excluded as well.
The sample size was chosen taking into consideration
reported mean differences in PD in the order of 0.5 to
1 mm between nonsurgical periodontal therapies with or
without adjunctive antibiotics [18, 19]. Assuming that the
common standard deviation is 1 mm, a sample of 30 per
group would provide 80 % power to detect a true difference
of 0.75 mm between groups.
Test products and randomization
PDTwas carried out in residual pockets using the Periowave™
System (Ondine Biomedical Inc., Vancouver, Canada). The
photosensitizing agent was methylene blue. Approximately
0.2 ml of the solution was applied over 60 s to each pocket
with a blunt-ended side-port irrigator. The site was illuminated
for 60 s to activate the agent using a disposable, light-diffusing
tip that was introduced into the pocket and was connected via a
fiber optic cable to a diode laser (λ 670 nm, 280 mWof output
power, stable to within ±0.2 dB over 60 s, and within ±0.3 dB
over successive cycles). The control treatment consisted of the
same procedure, except that the light-diffusing tip was kept in
the pocket for 60 s without activating the laser. All sites
received two rounds of treatment in an interval of 1 week.
The following protocols were randomly assigned using a
computer-generated table: A, the laser was activated during
both treatments; B, the laser was activated during the first
treatment only; and C, the laser was never activated.
Two clinicians performed the procedures involving a con-
tact with the patients. The examiner (GC) enrolled the partic-
ipants, recorded all data, and provided preliminary treatments;
the operator (VMC) delivered the test treatments. The treat-
ment assignments were concealed to the patient and the ex-
aminer. The operator was unaware of previously recorded data
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except the pocket depth measurements and was not involved
in the posttreatment evaluations.
Clinical protocol
In the first visit (pre-baseline), the examiner recorded the
medical history, removed supragingival deposits, and, if
necessary, gave oral hygiene instructions. Three quadrants
were selected as study quadrants. In each study quadrant,
the deepest pocket in the area between the first incisor and
the mesial aspect of the first molar with PD >4 mm, clinical
attachment loss (CAL) >1 mm, and BOP+ was designated
as the study site. Study sites in contralateral quadrants had to
be separated by at least two teeth.
The second visit (baseline) was scheduled within the next 7
to 10 days. The examiner first recorded the Plaque Index (PlI)
[20]. Then, he carefully removed supragingival plaque, iso-
lated the study sites from saliva with cotton rolls, and collected
a 20-s sample of GCF from each study site with a strip of
Durapore membrane (Millipore, Bedford, MA, USA) as pre-
viously described [16]. Next, the Gingival Index (GI) [21] was
assessed. A subgingival plaque sample was obtained by
inserting one paper point (Dentsply-Maillefer ISO 035) into
each study site. Finally, he recorded PD, BOP, and recession
(REC; positive if gingival margin located apical, negative if
located coronal to the cemento–enamel junction). Once com-
pleted, the operator took over. She opened an envelope with
the subject’s number to reveal the instructions for activating
the laser in the three study quadrants and for the sequence of
treatment. The residual pockets were debrided with an
ultrasonic scaler (EMS, Nyon, Switzerland), and PDT was
provided according to the instructions. Treatments were
performed under local anesthesia to the discretion of the
patient. After each quadrant, the operator noted the time and
asked the patient to rate pain/discomfort on a visual analog
scale (VAS) by placing a mark on a horizontal line, 100 mm
long, labeled with “no pain” at one end and with “worst pain”
at the other. The third session was scheduled after 1 week. The
operator applied the photosensitizer once again and activated
the laser according to protocols A–C.
The examiner reassessed the participants 3 and 6 months
after the treatment. Medical history, any concomitant med-
ication, and all adverse events were recorded. Clinical pa-
rameters were measured, and subgingival plaque and GCF
samples were obtained the same way as at baseline. The
samples were stored at −20 °C until processing.
Microbiological procedures
Genomic DNA was extracted using the GenElute Bacterial
Genomic DNA Kit (Sigma-Aldrich Co., St. Louis MO,
USA) in accordance with the manufacturer’s instructions.
Quantitative real-time PCR was performed to detect and
quantify six specific bacteria (Porphyromonas gingivalis,
Aggregatibacter actinomycetemcomitans, Tannerella for-
sythia, Treponema denticola, Prevotella intermedia,
Parvimonas micra) using species-specific primers [22, 23].
SYBR Green (Life Technologies, Carlsbad CA, USA) was
used as nucleic acid stain. Real-time PCR was carried out
using an ABI Prism® 7900HT Sequence Detection System
(Applied Biosystems, Foster City CA, USA). Bacterial
counts were calculated by comparison with homologous
reference. The detection limit was 1,000 cells/ml.
GCF analysis
GCF levels of 20 different biomarkers were determined
using a multiplex fluorescent bead-based immunoassay
and the Bio-Plex 200 suspension array system (BioRad
Laboratories, Hercules, CA, USA) as previously described
[16]. Cytokines and acute-phase proteins were measured
using the human cytokine 11-plex (Kit M5000HIVRK,
BioRad Laboratories, Hercules, CA, USA), the acute-
phase protein 5-plex (Kit 171A4009M, BioRad Laborato-
ries, Hercules, CA, USA), and the acute-phase protein
4-plex (Kit 171A4007M, BioRad Laboratories, Hercules,
CA, USA). The first panel included the following 11 cyto-
kines: Interleukin (IL)-1β, IL-1 receptor antagonist (IL-1ra),
IL-8, IL-17, basic fibroblast growth factor (b-FGF), granu-
locyte colony stimulating factor (G-CSF), granulocyte mac-
rophage colony stimulating factor (GM-CSF), interferon γ
(IFN-γ), macrophage inflammatory protein 1β (MIP-1β),
tumor necrosis factor α (TNF-α), and vascular endothelial
growth factor (VEGF). The second panel included nine
human acute-phase biomarkers in two assays: α 2 macro-
globulin (α2M), C-reactive protein (CRP), haptoglobin,
serum amyloid P, ferritin, fibrinogen, procalcitonin, serum
amyloid A, and tissue plasminogen activator. For the 11-
plex panel, the lowest limit of detection of the assay varied
between 1 and 2.24 pg/ml, except IL-1ra and TNF-α, where
the limits were 5.63 and 6.63 pg/ml, respectively. For the
acute-phase protein panel, the limit of detection was below
1.1 ng/ml, except for ferritin (3.0 pg/ml), procalcitonin
(0.9 pg/ml), and tissue plasminogen activator (0.16 pg/ml).
Readings below these limits were recorded as zero.
Statistical analysis
The primary endpoint was the presence or absence of
PD >4 mm with BOP+ after 6 months (persisting pockets
>4 mm of bleeding upon probing are commonly perceived
as needing further treatment in clinical practice). Secondary
outcomes included changes in PD, BOP+, CAL (=PD+
REC), the presence or absence of target microorganisms
above >1,000 (detection threshold), and >100.000 cells/ml
after 3 and 6 months. The Kruskal–Wallis one-way analysis
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of variance, the Mann–Whitney U test, or Fisher’s exact test
was used to determine differences between sites treated with
different procedures. The longitudinal changes were ana-
lyzed using the Wilcoxon matched-pairs signed-ranks test.
One statistical program package (IBM SPSS Statistics 19,
IBM Corporation, Somers, NY, USA) was used for all
statistical analyses. P values <0.05 were accepted for statis-
tical significance.
Results
Twenty-eight persons gave informed consent, were enrolled
in the study, and received treatment as allocated. One par-
ticipant was excluded shortly after therapy due to moving
abroad. All other 27 subjects completed the study. The
3-month data could not be recorded for one participant due
to temporary unavailability.
The mean age of the 27 participants was 62.8 years
(range 37 to 77). There were 14 males and 13 females.
Fourteen subjects were nonsmokers, and one was a former
smoker who quit more than 10 years ago. Four subjects
smoked less than ten cigarettes per day, while eight partic-
ipants smoked 20 or more cigarettes daily.
Table 1 shows the baseline characteristics of the 27
participants by treatment protocol. All 81 sites included in
the study had a PD >4 mm; 51 (63 %) of them were bleeding
upon probing in the visit the baseline data were recorded.
Ten out of the 81 sites (12 %) showed a PlI of 2 and none a
value of 3. Twelve sites scored GI=2 (15 %) and none
higher. The clinical status of the three groups was homoge-
neous and revealed no statistically significant differences.
Similarly, the six studied microorganisms showed no signif-
icant difference with regards to the frequency of detection
at >1,000 or >100.000 cells/ml between the three groups.
From baseline to month 3, therapy resulted in significant
and clinically relevant changes of PD (p<0.001), CAL
(p<0.001), and BOP+ (p<0.001). Table 2 shows the clinical
and microbiologic status in the study sites after 3 months by
treatment protocol. The mean PD amounted to 2.9, 2.8, and
3.5 mm in the three groups, respectively, the difference
being statistically significant between A and C (p=0.04)
and between B and C (p=0.03). No site in group A was
deeper than 4 mm and bled upon probing, whereas three
sites in group B, and three sites in group C, were still deeper
than 4 mm and bled upon probing. However, these differ-
ences did not reach a level of statistical significance. No
further significant clinical or microbiological differences
between protocols were observed.
Table 3 shows the clinical and microbiologic status after
6 months. The changes in PD, CAL, and BOP+ obtained
after 3 months were maintained; the differences of PD
between groups were, however, no more significant. No site
of group A was deeper than 4 mm and bled upon probing.
Two sites belonging to group B and four sites belonging to
group C were deeper than 4 mm and bled upon probing.
Each of these sites was found in a different person (five
individuals were male and one was female; four were
smokers, two were nonsmokers). Detection frequencies
and frequencies of sites with counts >100.000 cells/ml of
the studied microorganisms did not change between base-
line and 3 or 6 months in any of the three treatment groups.
The average total treatment time necessary per tooth at
visit 2 was 9 min, with a range between 6 and 15 min
depending on the accessibility of the tooth and the morphol-
ogy of the pocket. This included local anesthesia, when
requested, ultrasonic debridement and PDT. At visit 3, when
only PDT was applied, the average treatment time was
7 min, with a range between 3 and 12 min.
The perception of pain/discomfort, assessed on a VAS
from 1 to 100 mm, was 12 mm on average at the second
visit. Only two out of 27 patients rated pain/discomfort
>40 mm. One incidence was attributed to discomfort asso-
ciated with mechanical debridement and one to a feeling of
illumination in the eye, when a pocket mesial of a first
maxillary molar was irradiated. At visit 3, when patients
had only the PDT, the mean VAS score was 6 mm, and only
one subject requested anesthesia.
Table 4 shows the overall mean GCF levels of the 11
biomarkers assessed using the human cytokine 11-plex. No
Table 1 Clinical and microbiological baseline characteristics of the
study sites per treatment protocol. A, two irradiations; B, one irradia-
tion; C, no irradiation
A B C p valuea
Total nb 27 27 27 –
PD (mm)c 5.9 (0.9) 6.3 (1.3) 6.3 (1.5) n.s.
CAL (mm)c 7 (1.6) 7.9 (2.2) 7.6 (2) n.s.
PD >4 and BOP+b 16 20 15 n.s.
BOP+b 16 20 15 n.s.
PlI >0b 17 19 19 n.s.
GI >0b 22 22 20 n.s.
AA >1,000; >100.000b 2; 1 2; 1 2; 2 n.s.; n.s.
TF >1,000; >100.000b 26; 13 24; 15 26; 16 n.s.; n.s.
PG >1,000; >100.000b 27; 15 25; 17 27; 14 n.s.; n.s.
TD >1,000; >100.000b 24; 14 24; 14 26; 17 n.s.; n.s.
PI >1,000; >100.000b 22; 7 19; 12 19; 11 n.s.; n.s.
PM >1,000; >100.000b 27; 18 26; 15 27; 18 n.s.; n.s.
PD probing pocket depth; CAL clinical attachment level; BOP+ bleed-
ing on probing; PlI Plaque Index; GI Gingival Index; AA A.
actinomycetemcomitans; TF T. forsythia; PG P. gingivalis; TD T.
denticola; PI P. intermedia; PM P. micra
a Difference between groups
b Number of sites
cMean (standard deviation)
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significant changes were observed between baseline and 3
or 6 months after treatment, and the differences between
groups were not significant. Table 5 shows the overall
mean GCF levels of the nine biomarkers assessed using
the acute-phase protein panels. A significant decrease was
observed between baseline and 6 months after treatment
for CRP, serum amyloid A, fibrinogen, procalcitonin,
and α2M. When looking at the groups separately, CRP
was significantly lower at month 6 only after treatment
according to protocol A, the laser being activated twice
(p<0.05), the other differences between groups being
nonsignificant.
Discussion
The aim of this study was to evaluate the benefit of PDT
delivered as adjunct to ultrasonic debridement once or twice
in a 1-week interval. The trial was carried out in patients
with residual pockets, defined as sites with PD >4 mm and
BOP+ after prior periodontal treatment. Because the root
surfaces at these sites had been subjected to repeated thor-
ough scaling and root planing previously, and were evalu-
ated to be smooth and free of detectable calculus, scaling
and root planing was not performed as part of the protocol
of this study. The primary endpoint, i.e., the elimination of
sites with PD >4 mm and BOP+, was achieved to 100 % by
treatment according to protocol A: no such site was still
present after two irradiations with the laser after 3 and
6 months. Small numbers of sites with PD >4 mm and
BOP+, however, persisted in the other two groups. Signifi-
cant reductions in PD (Fig. 1) and BOP+ could be shown
after all the treatment procedures. Comparing the three
modalities, the only significant difference related to PD after
3 months, with better results observed in sites that received
active laser irradiation, either once (B) or twice (A), as
Table 2 Clinical and microbio-
logical findings 3 months after
treatment. A, two irradiations; B,
one irradiation; C, no irradiation
PD probing pocket depth; CAL
clinical attachment level; BOP+
bleeding on probing; PlI Plaque
Index; GI Gingival Index; AA A.
actinomycetemcomitans; TF T.
forsythia; PG P. gingivalis; TD





A B C p valuea
Total nb 26 26 26 –
PD (mm)c 2.9 (1.1) 2.8 (1.1) 3.5 (1.2) A–C, 0.04; B–C, 0.03
CAL (mm)c 3.7 (1.8) 4 (1.9) 4.7 (2) n.s.
PD >4 and BOP+b 0 3 3 n.s.
BOP+b 7 9 8 n.s.
PlI >0b 8 11 12 n.s.
GI >0b 11 11 14 n.s.
AA >1,000; >100.000b 3; 1 4; 4 2; 2 n.s.; n.s.
TF >1,000; >100.000b 26; 13 24; 10 24; 15 n.s.; n.s.
PG >1,000; >100.000b 26; 10 25; 8 25; 11 n.s.; n.s.
TD >1,000; >100.000b 24; 13 24; 10 24; 12 n.s.; n.s.
PI >1,000; >100.000b 23; 8 19; 10 20; 8 n.s.; n.s.
PM >1,000; >100.000b 26; 17 25; 12 25; 17 n.s.; n.s.
Table 3 Clinical and microbio-
logical findings 6 months after
treatment. A, two irradiations; B,
one irradiation; C, no irradiation
PD probing pocket depth; CAL
clinical attachment level; BOP+
bleeding on probing; PlI Plaque
Index; GI Gingival Index; AA A.
actinomycetemcomitans; TF T.
forsythia; PG P. gingivalis; TD





A B C p valuea
Total nb 27 27 27 –
PD (mm)c 3.1 (1.0) 2.9 (1.8) 3.4 (1.5) n.s.
CAL (mm)c 4.1 (1.6) 4.2 (2.8) 4.6 (2.2) n.s.
PD >4 and BOP+b 0 2 4 n.s.
BOP+b 10 7 10 n.s.
PlI >0b 11 12 12 n.s.
GI >0b 14 10 13 n.s.
AA >1,000; >100.000b 4; 2 4; 1 5; 3 n.s.; n.s.
TF >1,000; >100.000b 24; 12 22; 15 25; 14 n.s.; n.s.
PG >1,000; >100.000b 24; 11 25; 10 25; 15 n.s.; n.s.
TD >1,000; >100.000b 23; 13 23; 10 24; 13 n.s.; n.s.
PI >1,000; >100.000b 23; 10 22; 3 18; 11 n.s.; n.s.
PM >1,000; >100.000b 25; 14 25; 20 25; 18 n.s.; n.s.
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compared to no irradiation (C). However, at month 6, these
differences were no more significant. These results are in
accordance with one systematic review [12] revealing sta-
tistically significant PD reductions and clinical attachment
gain for adjunctive PDT after 3 months but not after
6 months.
Most of the previous trials included patients with
untreated chronic [24–28] or aggressive [17, 29] periodon-
titis. The participants of our trial, however, presented resid-
ual pockets despite previous therapy. Conceptually, it is
more challenging to obtain a further clinical improvement
in such sites than in previously untreated pockets. In an
earlier study, our group compared the effects of PDT in
residual pockets to thorough scaling and root planing or
diode soft laser therapy [30]. While all three treatments
resulted in a significant clinical improvement, PDT and
scaling and root planing resulted in fewer persisting pockets
after 6 months than diode soft laser application.
The concept of repeated application and activation of the
photosensitizer has been addressed in only few studies. In
one trial [15], three rounds of PDT within 1 week had no
significant effect on clinical and microbiological parame-
ters. In another trial [14], however, five rounds of adjunctive
PDT yielded better clinical outcomes than mechanical de-
bridement only in residual pockets of maintenance patients;
reductions of PD and BOP+, and gains in clinical attach-
ment level were greater in the test as compared to the control
group.
In the present study, the detection frequencies of the
studied microorganisms, and frequencies of elevated counts,
were not different before and after treatment, or between
treatment groups. Microbiological changes have been ana-
lyzed in other studies as well and were found to be hetero-
geneous. Two studies [24, 31] showed no group differences,
while two others [32, 33] detected significant differences for
Table 4 GCF levels of 11 biomarkers assessed using the human
cytokine 11-plex, expressed as mean (standard deviation) per 20-s
sample
Baseline Month 3 Month 6 p valuea
IL-1β (pg) 71 (109) 70 (103) 75 (101) n.s.
IL-1ra (pg) 6,795 (7214) 7,528 (6817) 7,859 (7423) n.s.
IL-8 (pg) 134 (179) 135 (166) 164 (204) n.s.
IL-17 (pg) 1.9 (3.1) 2.0 (3.2) 2.1 (3.0) n.s.
b-FGF (pg) 3.0 (4.3) 3.2 (3.9) 3 (3.5) n.s.
G-CSF (pg) 16.4 (43.5) 13.1 (28.5) 7.18 (15.8) n.s.
GM-CSF (pg) 10.5 (14.7) 11.6 (15.1) 11.6 (14.9) n.s.
IFN-γ (pg) 18.8 (14.7) 20.5 (20.4) 19.9 (13.9) n.s.
MIP-1β (pg) 7.0 (11.3) 6.3 (8.5) 6.6 (9.2) n.s.
TNF-α (pg) 2.9 (3.3) 2.7 (2.7) 3.2 (3.5) n.s.
VEGF (pg) 155 (170) 177 (245) 155 (133) n.s.
IL-1β interleukin 1β; IL-1ra interleukin 1 receptor antagonist; IL-
8 interleukin 8; IL-17 interleukin 17; b-FGF basic fibroblast growth
factor; G-CSF granulocyte colony stimulating factor; GM-CSF granu-
locyte macrophage colony stimulating factor; IFN-γ interferon γ;MIP-
1βmacrophage inflammatory protein-1β; TNF-α tumor necrosis factor
α; VEGF vascular endothelial growth factor
a Difference between baseline and month 3 or 6
Table 5 GCF levels of nine
acute-phase proteins, expressed





Baseline Month 3 Month 6 p valuea
α-2 Macroglobulin (ng) 255 (516) 157 (341) 104 (177) <0.05
C-reactive protein (ng) 0.3 (0.5) 0.2 (0.4) 0.1 (0.2) <0.05
Haptoglobin (ng) 141 (324) 183 (372) 140 (309) n.s.
Serum amyloid P (ng) 28 (51) 22 (45) 14 (36) n.s.
Ferritin (pg) 4,643 (6,513) 3,646 (5187) 3,829 (4,802) n.s.
Fibrinogen (ng) 86 (48) 90 (76) 73 (46) <0.05
Procalcitonin (pg) 19 (15) 18 (17) 14 (12) <0.05
Serum amyloid A (ng) 3.6 (1.8) 3.5 (1.5) 3.0 (1.2) <0.05
TP activator (pg) 160 (150) 158 (168) 175 (214) n.s.
Fig. 1 Longitudinal development of PD (probing pocket depth in
millimeter). n=26 participants. A Two irradiations. B One irradiation.
C No irradiation
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the investigated microorganisms. In our previous study [30],
PDT and scaling and root planing suppressed P. gingivalis,
T. forsythia, and T. denticola stronger than diode soft laser
therapy, but the results for PDT and scaling and root planing
did not differ significantly. In the present and previous trials
of our group, antibiotic treatment was not allowed during
2 months prior to baseline. To what extent a longer period of
confirmed nonexposure to antibiotics would have changed
the outcome is unknown.
We found a significant decrease between baseline
and month 6 for CRP, serum amyloid A, fibrinogen,
procalcitonin, and α2M. Significant reductions in GCF
levels of selected cytokines after nonsurgical periodontal
treatment with PDT have been reported previously [16,
17, 34], corresponding to the clinical improvement seen in
the periodontal status. However, similar levels were
reported when treatments with or without PDT were com-
pared. In the present study, when looking at the groups
separately, CRP was significantly lower only at 6 months
after treatment in sites treated according to protocol A, the
other differences between groups being nonsignificant. CRP
is not produced locally in the periodontal tissues; thus, its
presence in GCF and/or periodontal tissues is indicative of
systemic inflammation [35]. During periodontitis, bacteria
and their products enter the systemic circulation, eliciting the
production of a series of inflammatory biomarkers, such as
CRP, which eventually arrives at the site of inflammation.
Activating the laser twice may have further reduced the effect
of periodontal inflammation on systemic CRP.
The evaluation of pain/discomfort yielded an average score
of 12 at visit 2. One subject complained specifically about
feeling the irradiation in the eye, when the mesial site of a first
maxillary molar was treated with the laser. At visit 3, when
patients had only the PDT, mean VAS scores were very low,
and only one subject requested local anesthesia. However,
repeated mechanical instrumentation may cause significant
hard tissue damage cumulatively, whereas PDT only destroys
the biofilm, thus potentially inducing less dentine hypersensi-
tivity. In one study, it was even observed that laser irradiation
might reduce dentine hypersensitivity [36].
The average treatment time per tooth of 7 to 9 min
resulted in a cumulative session length that appears to be
compatible with a common recall session for periodontal
maintenance care, where typically one has to deal with
isolated residual pockets only. Following the Periowave™
operating procedure as advised, a 45–60-min session allows
treating five to seven teeth.
Within the limits of our study, we conclude that all three
treatments resulted in significant clinical improvement when
used in patients on periodontal maintenance. More studies
with sufficient statistical power should be conducted in
order to assess the possibilities of using PDT in various
forms of periodontal disease.
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